trending Market Intelligence /marketintelligence/en/news-insights/trending/n0pocafmw2wz4_g2epn4vg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alder Biopharmaceuticals names interim CEO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Alder Biopharmaceuticals names interim CEO

Alder Biopharmaceuticals Inc. appointed Paul Cleveland as interim president and CEO, effective March 20.

Cleveland will continue to serve as a director of Alder Biopharmaceuticals. His appointment was made after Randall Schatzman and the company's board decided that it was the right time for Schatzman to step down as president, CEO and director.

Schatzman has agreed to serve as a consultant to Alder Biopharmaceuticals for an interim period to ensure a smooth transition.

Alder Biopharmaceuticals has retained Russell Reynolds Associates, an executive search firm, to assist in the search for a permanent successor.

Cleveland currently serves as board chairman of Adverum Biotechnologies Inc., where he previously served as the president and CEO.

Bothell, Wash.-based Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes therapeutic antibodies in the U.S., Australia and Ireland.